What 5 Analyst Ratings Have To Say About Mainz Biomed
Portfolio Pulse from Benzinga Insights
In the last quarter, Mainz Biomed (NASDAQ:MYNZ) received 5 analyst ratings, with 2 being bullish and 3 somewhat bullish. The company has an average 12-month price target of $8.6, which has increased by 1.18% over the past month.
September 26, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mainz Biomed received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. In this case, Mainz Biomed received mostly positive ratings, which could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100